Payment overview · 2025
General Payments
$569.51
22 reported records · 9 companies
Healthcare provider profile · identity verified
Luis A Guzman
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1114297330
Verified facts
What the public records show
CMS Open Payments records show Luis A Guzman received $569.51 in general payments during 2025 across 22 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $161.91 | 28.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.99 | 21.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.68 | 12.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.72 | 12.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.88 | 10.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.46 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.25 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.80 | 3.1% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $13.82 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.51 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $183.15 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.72 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.44 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 183 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
183 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
183 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 682 | 223 |
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 208 |
| Lisinopril | Lisinopril | 522 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 111 |
| Losartan Potassium | Losartan Potassium | 357 | 108 |
| Metformin Hcl | Metformin Hcl | 212 | 75 |
| Gabapentin | Gabapentin | 209 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 74 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 196 | 61 |
| Furosemide | Furosemide | 193 | 61 |
| Jardiance | Empagliflozin | 183 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 183 | 57 |
| Omeprazole | Omeprazole | 175 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 53 |
| Montelukast Sodium | Montelukast Sodium | 156 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 28 |
| Ozempic | Semaglutide | 122 | 23 |
| Januvia | Sitagliptin Phosphate | 116 | 29 |
| Potassium Chloride | Potassium Chloride | 113 | 39 |
| Trazodone Hcl | Trazodone Hcl | 109 | 38 |
| Naproxen | Naproxen | 94 | 41 |
| Linzess | Linaclotide | 92 | 34 |
| Mounjaro | Tirzepatide | 90 | 18 |
| Meloxicam | Meloxicam | 84 | 26 |
| Trulicity | Dulaglutide | 82 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 27 |
| Tramadol Hcl | Tramadol Hcl | 73 | 16 |
| Glipizide | Glipizide | 71 | 27 |
| Rybelsus | Semaglutide | 70 | 18 |
| Allopurinol | Allopurinol | 69 | 24 |
| Prednisone | Prednisone | 66 | 44 |
| Finasteride | Finasteride | 64 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 34 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 62 | 20 |
| Ezetimibe | Ezetimibe | 58 | 25 |
| Carvedilol | Carvedilol | 57 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 22 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 28 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Eliquis | Apixaban | 49 | 14 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Cephalexin | Cephalexin | 44 | 35 |
| Hydrocortisone | Hydrocortisone | 44 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Glipizide Er | Glipizide | 43 | 17 |
| Donepezil Hcl | Donepezil Hcl | 42 | 17 |
| Benazepril Hcl | Benazepril Hcl | 41 | 13 |
| Famotidine | Famotidine | 41 | 12 |
| Spironolactone | Spironolactone | 39 | 14 |
| Azithromycin | Azithromycin | 36 | 29 |
| Pregabalin | Pregabalin | 36 | 14 |
| Sertraline Hcl | Sertraline Hcl | 33 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Lactulose | Lactulose | 27 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.51 · 22 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, MOUNJARO, NUVISION ICE CATHETER, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error